Abstract
Treatment with EGFR kinase inhibitors improves progression-free survival of patients with EGFR-mutant lung cancer. However, all patients with initial response will eventually acquire resistance and die from tumor recurrence. We found that intermittent high-dose treatment with erlotinib induced apoptosis more potently and improved tumor shrinkage significantly than the established low doses. In mice carrying EGFR-mutant xenografts intermittent high-dose treatment (200 mg/kg every other day) was tolerable and prolonged progression-free survival and reduced the frequency of acquired resistance. Intermittent EGFR-targeted high-dose schedules induce more profound as well as sustained target inhibition and may afford enhanced therapeutic efficacy.
Keywords:
EGFR; NSCLC; PET; erlotinib; high-dose scheduling.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Cell Line, Tumor
-
Disease-Free Survival
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
ErbB Receptors / metabolism
-
Erlotinib Hydrochloride / administration & dosage*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Male
-
Mice
-
Mice, Nude
-
Protein Kinase Inhibitors / administration & dosage*
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
EGFR protein, mouse
-
ErbB Receptors